Press releases, workshop summaries, and editorials

Accelerating Medicines Partnership launches data knowledge portal for Parkinson’s disease

Shared platform to catalyze research collaboration toward biomarker discovery to advance the development disease therapies

AMP PD

The Accelerating Medicines Partnership (AMP) program for Parkinson’s disease (PD) has launched a data portal to provide de-identified information collected from 4,298 PD patients and healthy controls to researchers working to develop effective therapies for the disease. The portal enables researchers to study complex data sets and perform genome-wide analyses at a scale previously impossible.

Accelerating Research for Parkinson’s Disease

The Accelerating Medicines Partnership Parkinson's disease (AMP PD) program, launched on Jan 30, 2018, is the most ambitious initiative so far to find a cure for Parkinson's disease. Formed by the US National Institutes of Health (NIH), the US Food and Drug Administration (FDA), five biopharmaceutical and life science companies, and the Michael J. Fox Foundation, this partnership is focused on discovering novel therapeutic targets and on developing biomarkers to help validate existing therapeutic targets for Parkinson's disease.

AMP PD

 

NIH launches partnership to improve success of clinical trials for patients with Parkinson’s disease

“Advancing treatments for Parkinson’s disease is hampered by insufficient understanding of biological networks; drugs aimed at seemingly promising therapeutic targets fail in clinical trials,” said NIH Director Francis S. Collins, M.D., Ph.D. “By combining our expertise and resources, AMP PD partners hope to increase our collective odds of success in accelerating the development of effective treatments for a million Americans who suffer from this debilitating disease.”

NINDS Parkinson's Disease Biomarkers Program Meeting, Bethesda MD (September 22, 2014)

On August 8-9, 2016, representatives from NIH,  Principal Investigators (PIs), advocacy groups, industry, as well as clinical and data management experts from each project sponsored under the National Institute of Neurological Disorders and Stroke (NINDS) Parkinson’s Disease (PD) Biomarkers Program (PDBP) met to discuss progress over the last twelve months in addition to current and future plans for the program. 

NINDS Parkinson's Disease Biomarkers Program Consortium Meeting, Bethesda MD (August 8-9, 2016)

On August 8-9, 2016, representatives from NIH,  Principal Investigators (PIs), advocacy groups, industry, as well as clinical and data management experts from each project sponsored under the National Institute of Neurological Disorders and Stroke (NINDS) Parkinson’s Disease (PD) Biomarkers Program (PDBP) met to discuss progress over the last twelve months in addition to current and future plans for the program.